IJU Case Reports最新文献_第10页

Metastasis-Directed Surgery for Solitary Pulmonary Metastasis After Pembrolizumab in Urothelial Carcinoma: A Case Report. 转移导向手术治疗派姆单抗后尿路上皮癌的孤立性肺转移：一例报告。

IF 0.5

IJU Case Reports Pub Date : 2026-05-27 eCollection Date: 2026-06-01 DOI: 10.1002/iju5.70201

Kohji Takemura, Makoto Tanaka, Yosuke Hamada, Takahiro Karasaki, Kazushige Sakaguchi, Hironori Uruga, Shinji Urakami, Sakashi Fujimori, Keita Uchino

{"title":"Metastasis-Directed Surgery for Solitary Pulmonary Metastasis After Pembrolizumab in Urothelial Carcinoma: A Case Report.","authors":"Kohji Takemura, Makoto Tanaka, Yosuke Hamada, Takahiro Karasaki, Kazushige Sakaguchi, Hironori Uruga, Shinji Urakami, Sakashi Fujimori, Keita Uchino","doi":"10.1002/iju5.70201","DOIUrl":"10.1002/iju5.70201","url":null,"abstract":"Introduction: The role of metastasis-directed therapy in urothelial carcinoma remains uncertain, particularly in the immune checkpoint inhibitor era. We report a case of solitary pulmonary metastasis that developed after a favorable response to pembrolizumab and was managed with metastasectomy.Case presentation: A 65-year-old man with ureteral carcinoma underwent radical nephroureterectomy followed by adjuvant gemcitabine plus carboplatin. Three months later, a solitary pulmonary metastasis was detected and pembrolizumab was initiated. After initial enlargement, the lesion regressed and achieved a partial response after 13 cycles, followed by slight regrowth after 18 cycles, consistent with oligoprogression. Video-assisted thoracoscopic metastasectomy was performed 14 months after pembrolizumab initiation. Pembrolizumab was continued for 1 year postoperatively, with no recurrence observed 17 months after surgery.Conclusion: This case suggests that metastasis-directed therapy may be a reasonable option for carefully selected patients with oligoprogressive urothelial carcinoma during immune checkpoint inhibitor therapy.","PeriodicalId":52909,"journal":{"name":"IJU Case Reports","volume":"9 4","pages":"e70201"},"PeriodicalIF":0.5,"publicationDate":"2026-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13240404/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148200918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

IJU Case Reports Pub Date : 2026-05-27

引用次数: 0

Neuroendocrine Transformation Without PSA Elevation in High-Risk Metastatic Castration-Sensitive Prostate Cancer Under Androgen Receptor Signaling Inhibition: A Case Report. 在雄激素受体信号抑制下，高危转移性去势敏感前列腺癌的神经内分泌转化无PSA升高：1例报告。

IF 0.5

IJU Case Reports Pub Date : 2026-05-27 eCollection Date: 2026-06-01 DOI: 10.1002/iju5.70196

Yoshihiro Nakagami, Shintaro Ohnuma, Masashi Tamaoka, Tatsuki Inoue, Motoki Yamagishi, Kazuhiko Oshinomi, Masakazu Nagata, Yasuyuki Oohira, Toshiko Yamochi, Takashi Fukagai

{"title":"Neuroendocrine Transformation Without PSA Elevation in High-Risk Metastatic Castration-Sensitive Prostate Cancer Under Androgen Receptor Signaling Inhibition: A Case Report.","authors":"Yoshihiro Nakagami, Shintaro Ohnuma, Masashi Tamaoka, Tatsuki Inoue, Motoki Yamagishi, Kazuhiko Oshinomi, Masakazu Nagata, Yasuyuki Oohira, Toshiko Yamochi, Takashi Fukagai","doi":"10.1002/iju5.70196","DOIUrl":"10.1002/iju5.70196","url":null,"abstract":"Introduction: Neuroendocrine prostate cancer is a rare and highly aggressive variant of prostate cancer with a poor prognosis. We report a case in which metastatic castration-sensitive prostate cancer directly transformed into neuroendocrine prostate cancer without a corresponding increase in prostate-specific antigen.Case presentation: An 86-year-old male with severe acute renal failure demonstrated a prostate-specific antigen level of 306 ng/mL and a Gleason score of 4 + 5 on prostate biopsy. Imaging revealed lung, bone, and lymph node metastases, leading to a diagnosis of high-risk metastatic castration-sensitive prostate cancer. Abiraterone acetate was initiated immediately. Nineteen months later, multiple liver metastases were detected despite stable prostate-specific antigen levels. The patient died 4 months later. Autopsy revealed widespread metastases, all histologically confirmed as neuroendocrine prostate cancer.Conclusion: Strong androgen receptor suppression in metastatic castration-sensitive prostate cancer can lead to aggressive radiographic progression without prostate-specific antigen elevation, underscoring the limitations of antigen-based monitoring.","PeriodicalId":52909,"journal":{"name":"IJU Case Reports","volume":"9 4","pages":"e70196"},"PeriodicalIF":0.5,"publicationDate":"2026-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13240478/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148200969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

IJU Case Reports Pub Date : 2026-05-25

引用次数: 0

Malignant/Sarcomatous Transformation of Mixed Epithelial and Stromal Tumor of the Kidney: A Case Report. 肾上皮和间质混合瘤的恶性/肉瘤转化1例报告。

IF 0.5

IJU Case Reports Pub Date : 2026-05-25 eCollection Date: 2026-06-01 DOI: 10.1002/iju5.70194

Kentaro Arinami, Kozue Ito, Go Hasegawa, Yurie Takizawa, Yohei Ikeda, Noboru Hara, Tsutomu Nishiyama

引用次数: 0

IJU Case Reports Pub Date : 2026-05-25

引用次数: 0

Pathological Complete Response to Nivolumab Plus Ipilimumab Combination Therapy in Advanced Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus. 纳武单抗加伊匹单抗联合治疗晚期肾癌伴下腔静脉肿瘤血栓的病理完全缓解。

IF 0.5

IJU Case Reports Pub Date : 2026-05-20 eCollection Date: 2026-05-01 DOI: 10.1002/iju5.70200

Takuto Tsuchiya, Go Kimura, Hayato Takeda, Jun Akatsuka, Hiroya Hasegawa, Yuka Toyama, Takashi Sakatani, Akira Shimizu, Ryuji Ohashi, Yukihiro Kondo

{"title":"Pathological Complete Response to Nivolumab Plus Ipilimumab Combination Therapy in Advanced Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus.","authors":"Takuto Tsuchiya, Go Kimura, Hayato Takeda, Jun Akatsuka, Hiroya Hasegawa, Yuka Toyama, Takashi Sakatani, Akira Shimizu, Ryuji Ohashi, Yukihiro Kondo","doi":"10.1002/iju5.70200","DOIUrl":"10.1002/iju5.70200","url":null,"abstract":"Introduction: Nivolumab plus ipilimumab is a standard first-line regimen for advanced renal cell carcinoma; however, primary tumors often respond less favorably to this combination than to immune checkpoint inhibitor-tyrosine kinase inhibitor regimens, and pathological complete response is rare.Case presentation: A 78-year-old man presented with abdominal pain. Computed tomography revealed a 91-mm right renal mass with a Neves level 3 inferior vena cava tumor thrombus. Needle biopsy confirmed clear cell renal cell carcinoma with diffuse programmed death-ligand 1 expression, and both the tumor proportion and combined positive scores were approximately 100%. Nivolumab plus ipilimumab was administered. After 21 months, the primary tumor decreased in size by 68.1% and tumor thrombus regressed from level 3 to 1. Histopathological examination following radical nephrectomy with tumor thrombectomy demonstrated a pathological complete response.Conclusion: Diffuse programmed death-ligand 1 expression on pretreatment biopsy may have been associated with a favorable response to nivolumab plus ipilimumab.","PeriodicalId":52909,"journal":{"name":"IJU Case Reports","volume":"9 3","pages":"e70200"},"PeriodicalIF":0.5,"publicationDate":"2026-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13239876/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148200877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Concurrent Bladder Urothelial Carcinoma and Prostate Tuberculosis: A Case Report. 膀胱尿路上皮癌并发前列腺结核1例报告。

IF 0.5

IJU Case Reports Pub Date : 2026-05-15 eCollection Date: 2026-05-01 DOI: 10.1002/iju5.70195

Rikuo Suzuki, Taketo Kawai

{"title":"Concurrent Bladder Urothelial Carcinoma and Prostate Tuberculosis: A Case Report.","authors":"Rikuo Suzuki, Taketo Kawai","doi":"10.1002/iju5.70195","DOIUrl":"10.1002/iju5.70195","url":null,"abstract":"Introduction: Tuberculosis is associated with an increased risk of bladder cancer; however, the simultaneous occurrence of urogenital tuberculosis and bladder cancer is rare. Primary prostate tuberculosis is relatively uncommon in patients with urogenital tuberculosis.Case presentation: A 68-year-old man presented with gross hematuria and irritative voiding symptoms. Cystoscopy revealed a bladder tumor. The PSA level was elevated (8.32 ng/mL), and MRI findings suggested prostate cancer. Chest radiography and CT indicated pulmonary tuberculosis, which was confirmed by sputum mycobacterial culture and PCR. Urine mycobacterial cultures revealed urinary tuberculosis. TURBT and prostate biopsy were performed after initiating treatment for tuberculosis and confirming sputum conversion. Histopathological examination revealed urothelial carcinoma of the bladder and prostate tuberculosis.Conclusion: This is the first reported case of concurrent bladder urothelial carcinoma and prostate tuberculosis. Patients with pulmonary tuberculosis may benefit from evaluation for urogenital tuberculosis, including prostatic involvement, and consideration of coexisting urothelial carcinoma.","PeriodicalId":52909,"journal":{"name":"IJU Case Reports","volume":"9 ","pages":"e70195"},"PeriodicalIF":0.5,"publicationDate":"2026-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13179123/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147965355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Rapid Systemic Progression After Ureteroscopic Holmium:YAG Laser Ablation for High-Grade Upper Tract Urothelial Carcinoma in a Solitary Kidney: A Case Report. 输尿管镜下钬：YAG激光消融治疗高级别上尿路上皮癌单侧肾后的快速全身进展：1例报告。

IF 0.5

IJU Case Reports Pub Date : 2026-05-14 eCollection Date: 2026-05-01 DOI: 10.1002/iju5.70193

Shinichi Takebe, Nanaho Demizu, Mei Tokumoto, Ryota Morinaga, Taku Mitome, Akitoshi Takizawa

{"title":"Rapid Systemic Progression After Ureteroscopic Holmium:YAG Laser Ablation for High-Grade Upper Tract Urothelial Carcinoma in a Solitary Kidney: A Case Report.","authors":"Shinichi Takebe, Nanaho Demizu, Mei Tokumoto, Ryota Morinaga, Taku Mitome, Akitoshi Takizawa","doi":"10.1002/iju5.70193","DOIUrl":"10.1002/iju5.70193","url":null,"abstract":"Introduction: Endoscopic kidney-sparing management is increasingly being used for upper tract urothelial carcinoma; however, its use in high-grade diseases remains challenging.Case presentation: An 82-year-old man with a solitary left kidney underwent transurethral lithotripsy for left renal and ureteral stones 25 years after right nephroureterectomy for ureteral carcinoma. A 15-mm papillary tumor was incidentally detected in the upper calyx and partially ablated using a holmium:YAG laser after biopsy. Biopsy revealed a high-grade urothelial carcinoma. Because the patient had a solitary kidney, radical nephroureterectomy would have necessitated dialysis. Therefore, ureteroscopic laser ablation was performed after counseling. A second laser ablation was performed 2 months later. Twelve days later, imaging revealed an enlarged renal pelvic tumor with multiple metastases. Despite receiving gemcitabine plus carboplatin chemotherapy, the patient died.Conclusion: Ureteroscopic ablation for high-grade upper tract urothelial carcinoma may offer limited cancer control and can be followed by extremely rapid systemic progression.","PeriodicalId":52909,"journal":{"name":"IJU Case Reports","volume":"9 ","pages":"e70193"},"PeriodicalIF":0.5,"publicationDate":"2026-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13175678/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147965362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Vibegron for Anticholinergic-Resistant Pediatric Neurogenic Lower Urinary Tract Dysfunction After Spinal Cord Amputation: A Case Report. Vibegron治疗脊髓截肢后抗胆碱能耐药儿童神经源性下尿路功能障碍1例。

IF 0.5

IJU Case Reports Pub Date : 2026-05-14 eCollection Date: 2026-05-01 DOI: 10.1002/iju5.70185

Kohei Mori, Izuru Shiba, Haruko Miyazawa, Noriaki Samejima, Koga Horiuchi, Hirokazu Ishikawa, Yutaka Shiono, Kazumasa Matsumoto

{"title":"Vibegron for Anticholinergic-Resistant Pediatric Neurogenic Lower Urinary Tract Dysfunction After Spinal Cord Amputation: A Case Report.","authors":"Kohei Mori, Izuru Shiba, Haruko Miyazawa, Noriaki Samejima, Koga Horiuchi, Hirokazu Ishikawa, Yutaka Shiono, Kazumasa Matsumoto","doi":"10.1002/iju5.70185","DOIUrl":"10.1002/iju5.70185","url":null,"abstract":"Introduction: Pediatric neurogenic lower urinary tract dysfunction (NLUTD) is commonly managed with anticholinergic agents and clean intermittent catheterization (CIC). However, treatment options are limited for patients who remain resistant to conventional therapy, particularly following spinal cord surgery.Case presentation: A 14-year-old boy with myelomeningocele underwent vertebral resection and spinal cord amputation. Despite CIC and solifenacin, he continued to experience daily urinary incontinence. 1 year postoperatively, his symptoms worsened and urinalysis became abnormal. Video-urodynamic study showed reduced bladder compliance and progression of bladder deformity. Vibegron 50 mg once daily was initiated. At 12 weeks, bladder capacity increased and compliance improved. Over 24 months, no urinary tract infections, incontinence episodes, or drug-related adverse events occurred.Conclusion: This case suggests that vibegron may be an effective, well-tolerated add-on therapy for pediatric patients with anticholinergic-resistant NLUTD after spinal cord surgery, improving bladder function and morphology while helping maintain quality of life.","PeriodicalId":52909,"journal":{"name":"IJU Case Reports","volume":"9 ","pages":"e70185"},"PeriodicalIF":0.5,"publicationDate":"2026-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13173764/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147965420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0